title: Examining the Saskatchewan health drug database for antidepressant use: the case of fluoxetine.
abstract: OBJECTIVE
  To examine the use of fluoxetine in an adult population in Saskatchewan.
  
  
  METHODS
  All adults in the Saskatchewan health care databases who had begun fluoxetine therapy between January 1992 and June 1996 and had not received an antidepressant in the six months before the index fluoxetine prescription were identified. Fluoxetine use for the subsequent six-month period was examined. The rates of completion of six months of fluoxetine, rates of stopping, switching to another serotonin-selective reuptake inhibitor (SSRI) or other class of antidepressant, resumption of fluoxetine, as well as average dosages taken and mean duration of therapy were determined. Rates were summarized as means with standard deviation.
  
  
  RESULTS
  Data were obtained for 11,322 subjects, of whom 68.2% were women; 17.4% were 65 years of age or older. The average prescribed daily dose of fluoxetine was 22.5 mg (SD=21.7) and the average duration was 88.1 days (SD=57.2). Only 18.9% of patients filled prescriptions for six months, 7049 (62.3%) stopped fluoxetine at least once for one month or more, and 17.3% were titrated to a higher dose, on average 71 days (SD=44) after the initiation of fluoxetine. The proportion of patients switching to another antidepressant was 13.6% (3.3% to another SSRI, 10.3% to other classes), after a mean of 69 days (SD=51) of fluoxetine treatment.
  
  
  CONCLUSIONS
  The authors' data suggest that there is a potential underutilization of fluoxetine in the study population. Further research may be warranted to determine the proportion of depressed patients in this population and to better understand the stop-switch-resume pattern of antidepressant use.
authors.affiliation: Faculty of Health Sciences, McMaster University, Hamilton, Canada.
authors.forename: R T
authors.initials: RT
authors.lastname: Joffe
authors.forename: M
authors.initials: M
authors.lastname: Iskedjian
authors.forename: T R
authors.initials: TR
authors.lastname: Einarson
authors.forename: B J
authors.initials: BJ
authors.lastname: O'Brien
authors.forename: M R
authors.initials: MR
authors.lastname: Stang
mesh_terms: D017677:Age Distribution; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016208:Databases, Factual; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017891:Pharmacoepidemiology / Q000706:statistics & numerical data*; D012525:Saskatchewan; D017678:Sex Distribution
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine